Generic Name and Formulations:
Streptozocin 1g/vial; pwd for IV inj or infusion after reconstitution/dilution; preservative-free.
Indications for ZANOSAR:
Symptomatic or progressive metastatic pancreatic islet cell cancer.
1g/m2 IV once weekly for 2 weeks; may repeat weekly; max 1.5g/m2 per dose. Or, 500mg/m2 IV daily for 5 days every 6 weeks until max benefit or toxicity.
Should be administered under the supervision of an experienced physician. Have access to a facility with laboratory and supportive resources sufficient to monitor drug tolerance and toxicity. Mutagenic, tumorigenic, or carcinogenic.
Renal dysfunction or disease. Monitor renal function (eg, urinalysis, BUN, creatinine, electrolytes) before, weekly during, and for 4 weeks after therapy; discontinue or reduce dose if significant renal toxicity occurs (see full labeling). Obtain CBCs, liver function tests weekly. Avoid extravasation. Ensure adequate hydration. Elderly. Pregnancy (Cat.D). Nursing mothers: not recommended.
Avoid concomitant nephrotoxic agents. Additive toxicity with other cytotoxic drugs. Severe bone marrow toxicity with doxorubicin. Phenytoin may reduce cytotoxicity.
GI upset (may be severe); hematological, hepatic and renal (cumulative and dose-related; may be fatal) toxicity; glucose intolerance, nephrogenic diabetes insipidus, inj site reactions, CNS effects (eg, confusion, lethargy, depression).
Sign Up for Free e-newsletters
- Study Finds Association Between Folate Intake and Risk of Cutaneous Melanoma
- Qualitative Analysis of Myeloma Patients' Experience Following Hematopoietic Stem Cell Transplant
- Melanoma Outcomes Improved With Nivolumab Alone or Plus Ipilimumab
- Involved-Field Radiotherapy Plus Chemotherapy Prolonged PFS in Follicular Lymphoma
- Patient Fears of Placebo Use in Clinical Trials
- Implementing an Ambulatory Adherence Program May Improve Oral Anticancer Medications Compliance
- Exercise Habits Influence Mortality in Adult Survivors of Childhood Cancer
- Managing Dyspnea With Fentanyl in Patients With Cancer at End of Life
- CALM: A Depression Intervention for Cancer Patients at the End of Life
- High BMI Among Premenopausal Women May Improve Risk for Breast Cancer
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|